<i>DNMT3A</i> mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera
Abstract
Abstract DNMT3A mutations in patients with polycythemia vera were heterogeneous and not enriched in interferon alfa–treated patients. DNMT3A mutations had no detectable impact on the hematologic response, molecular response, or survival outcomes.
Article Details
Authors (9)
Ghaith Abu-Zeinah
1Weill Cornell Medicine, New york city, United States
Katie Erdos
2Richard T. Silver, MD Myeloproliferative Neoplasms Center, Weill Cornell Medicine, New York, United States
Neville Lee
2Richard T. Silver, MD Myeloproliferative Neoplasms Center, Weill Cornell Medicine, New York, United States
Yara Ganom
1Division of Hematology and Medical Oncology, Richard T. Silver MD Myeloproliferative Neoplasms Center, Weill Cornell Medicine, New York, NY
Christoph Klade
38AOP Health, Vienna, Austria
Kurt Krejcy
38AOP Health, Vienna, Austria
Heinz Gisslinger
8Medical University of Vienna, Vienna, Austria
Richard T. Silver
1Division of Hematology and Medical Oncology, Richard T. Silver MD Myeloproliferative Neoplasms Center, Weill Cornell Medicine, New York, NY
Joseph M. Scandura
1Division of Hematology and Medical Oncology, Richard T. Silver MD Myeloproliferative Neoplasms Center, Weill Cornell Medicine, New York, NY